Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 12/20 | 0.51 |
| ▸ | EHMT1 | Q9H9B1 | 12/20 | 0.51 |
| ▸ | SPIN1 | Q9Y657 | 5/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.45 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL20720779 | 0.81 | EHMT2 (0.51) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL20720673 | 0.80 | EHMT2 (0.54) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| Formic Acid SCHEMBL19260658 | 0.79 | EHMT2 (0.55) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL19260641 | 0.79 | CACNA2D1 (0.58) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL20720603 | 0.78 | EHMT2 (0.58) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| Formic Acid SCHEMBL20720689 | 0.76 | EHMT2 (0.69) | EHMT2SPIN1 | |
| SCHEMBL20720690 | 0.75 | SPIN1 (0.51) | EHMT2EHMT1SPIN1 | |
| Formic Acid SCHEMBL19260687 | 0.75 | EHMT2 (0.48) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL19260611 | 0.75 | EHMT2 (0.73) | EHMT2SPIN1 | |
| SCHEMBL19260594 | 0.75 | EHMT2 (0.70) | EHMT2SPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EHMT2 2/4885EHMT1 1/4885SPIN1 599/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EHMT2 2/4885EHMT1 1/4885SPIN1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.